Skip to main content
Medesis Pharma S.A. logo

Medesis Pharma S.A. — Investor Relations & Filings

Ticker · ALMDP ISIN · FR0010844464 LEI · 969500C15M96P00UR648 PA Manufacturing
Open in API
Filings indexed 118 across all filing types
Latest filing 2021-08-26 Legal Proceedings Report
Country FR France
Listing PA ALMDP

About Medesis Pharma S.A.

https://www.medesispharma.com/

Medesis Pharma is a clinical-stage pharmaceutical biotechnology company focused on developing treatments for serious diseases using its proprietary AONYS® drug delivery platform. The AONYS® technology is a micro-emulsion designed for buccal (oral) administration, enabling the intracellular delivery of various therapeutic molecules, including metal ions, interfering RNAs, and peptides. A key feature of the platform is its ability to transport active ingredients across the blood-brain barrier, making it a promising approach for neurological disorders. The company's development pipeline addresses diseases with high unmet medical needs, including neurodegenerative conditions like Alzheimer's disease and therapies for individuals exposed to nuclear radiation.

Recent filings

Filing Released Lang Actions
MEDESIS PHARMA : NANOMANGANESE DEVELOPMENT PROGRAM REPOSITIONNED OUTSIDE OF EU POST ANSM AUTHORISATION DENIED
Legal Proceedings Report Classification · 95% confidence The document is a press release dated August 26, 2021, announcing a strategic repositioning of the NanoManganese development program outside the EU following the denial of clinical trial authorization by the French ANSM and Hungarian authorities. It details the reasons for the denial (lack of pharmacokinetics data) and the company's subsequent decision. This type of announcement, detailing a significant operational or strategic development, often related to clinical trials or regulatory setbacks, fits best under the general category of Regulatory Filings (RNS) or potentially Legal Proceedings Report (LTR) if it were focused on a lawsuit, but here it is a regulatory setback announcement. Since it is not a full financial report (10-K, IR), an earnings release (ER), or a management discussion (MDA), and it concerns a specific regulatory/clinical development, RNS is the most appropriate general regulatory announcement category, as it doesn't fit the more specific categories like DIRS, DIV, or CAP. Given the content is a direct announcement of a regulatory decision impacting development, RNS serves as the best fit among the provided options for a non-standard, material corporate update.
2021-08-26 English
MEDESIS PHARMA : BILAN SEMESTRIEL DU CONTRAT DE LIQUIDITE
Transaction in Own Shares Classification · 99% confidence The document is titled "MEDESIS PHARMA : BILAN SEMESTRIEL DU CONTRAT DE LIQUIDITE" (MEDESIS PHARMA: SEMI-ANNUAL BALANCE OF THE LIQUIDITY AGREEMENT) and reports on the status and transactions under a liquidity contract as of 30/06/2021. This type of report details the activity of a market maker or liquidity provider over a specific period (in this case, the first semester of 2021). This content is highly specific and relates to the management of the company's own shares or market stability, which aligns best with the 'Transaction in Own Shares' (POS) category, as liquidity contracts often involve the firm buying or selling its own shares to maintain market depth. It is not a general financial report (10-K, IR), an earnings release (ER), or a management discussion (MDA). It is a specific regulatory/contractual disclosure regarding share transactions.
2021-07-13 French
MEDESIS PHARMA : COMPTE-RENDU ASSEMBLÉE GÉNÉRALE MIXTE DU 15 JUIN 2021
AGM Information Classification · 98% confidence The document is explicitly titled "COMPTE-RENDU ASSEMBLÉE GÉNÉRALE MIXTE DU 15 JUIN 2021" (Minutes of the Combined General Meeting of June 15, 2021). It details the proceedings, the quorum achieved, the management's review of activities (COVID-19 programs, Alzheimer's treatment), and most importantly, provides a detailed table of the voting results for all resolutions presented during the meeting. This content perfectly matches the description of an Annual General Meeting (AGM) document, specifically the minutes or report summarizing the meeting and voting outcomes. The closest category is AGM-R (AGM Information), although it also contains voting results (DVA). Since it is the full report/minutes of the meeting itself, AGM-R is the primary classification, as DVA is usually just the results announcement, whereas this is the comprehensive meeting report.
2021-06-15 French
MEDESIS PHARMA : le plan de développement de son candidat médicament pour le traitement de la maladie de Huntington reçoit un avis favorable de l’Agence Européenne du Médicament
Regulatory Filings Classification · 95% confidence The document is a press release dated June 3, 2021, announcing that Medesis Pharma's development plan for its Huntington's disease drug candidate (NanosiRNA HD) received a favorable opinion from the European Medicines Agency (EMA) Scientific Committee. This is a specific announcement regarding regulatory/scientific progress for a drug candidate, not a full financial report (10-K, IR), an earnings release (ER), or a general regulatory filing (RNS). It details scientific progress, regulatory interaction (EMA opinion), and future clinical timelines. This type of announcement, focusing on scientific/regulatory milestones for a specific product, is best classified as a general Regulatory Filing (RNS) or potentially a Legal/Regulatory Update (LTR) if it were about litigation, but given the context of drug development milestones, RNS serves as the most appropriate general regulatory announcement category when a more specific code like 'Clinical Trial Update' is unavailable. Since it is a formal announcement of a significant regulatory/scientific event, RNS is the best fit among the provided options, as it is not a core financial report or management change.
2021-06-03 French
MEDESIS PHARMA: the development plan of its drug candidate for the treatment of Huntington’s Disease receives a positive opinion from the European Medicines Agency
Regulatory Filings Classification · 95% confidence The document is a press release dated June 3, 2021, announcing that Medesis Pharma's drug candidate for Huntington's Disease received a 'positive opinion' from the European Medicines Agency's Scientific Committee regarding its development plan. This is a specific, material corporate event announcement concerning regulatory/scientific progress, not a full financial report (like 10-K or IR), a transcript (CT), or a general regulatory filing (RNS). It details scientific progress and regulatory milestones, which aligns best with an announcement related to drug development or corporate progress that isn't strictly management change or financing. Given the options, this type of announcement, focusing on scientific/regulatory progress for a drug candidate, is often categorized under general corporate news or regulatory updates. Since there isn't a specific 'Drug Development Update' code, and it is a formal announcement of a significant milestone, it fits best as a general Regulatory Filing (RNS) or potentially a Capital/Financing Update (CAP) if it were tied to funding, but here it is purely scientific/regulatory progress. However, RNS is defined as 'General regulatory announcements and fallback category for miscellaneous filings that do not neatly fit into other specific categories.' This is a specific announcement of a regulatory opinion, making RNS the most appropriate fallback classification.
2021-06-03 English
MEDESIS PHARMA : Assemblée Générale Mixte du 15 juin 2021
AGM Information Classification · 98% confidence The document is titled "ASSEMBLEE GENERALE MIXTE DU 15 JUIN 2021" (Mixed General Meeting of June 15, 2021) and discusses the modalities for making preparatory documents available and consulting them, specifically mentioning the convocation of a General Meeting (AGM). It details how shareholders can vote (by correspondence) due to COVID-19 restrictions and confirms that the required legal documents are made available to shareholders and published on the company website. This content directly relates to the procedures and information surrounding an Annual General Meeting. Therefore, the appropriate classification is AGM Information (AGM-R). The document length (4619 chars) is not the primary factor, but the explicit subject matter confirms the classification over a mere announcement (RPA/RNS).
2021-05-28 French

Browse filings by year

5 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.